Currency
  • Loading...
Weather
  • Loading...
Air Quality (AQI)
  • Loading...

Scientists at the Moscow Institute of Physics and Technology (MIPT) and the Joint Institute for Nuclear Research have developed gold and silver nanoparticles that may enhance radiotherapy for breast cancer. In experiments, their use allowed the radiation dose to be reduced by up to one and a half times without losing the anti-tumor effect, according to reports citing Izvestia.

Key Takeaways: MIPT and the Joint Institute for Nuclear Research developed gold and silver nanoparticles; the particles are coated with beta-cyclodextrin derived from starch; the strongest effect was observed in triple-negative breast cancer; preliminary tests showed only weak effects on blood cells.

Radiotherapy remains a central treatment for many cancers, but higher doses can damage healthy tissue and increase side effects. The nanoparticles enter cancer cells and make them more sensitive to X-ray radiation; as a result, radiation damages tumor cell DNA more strongly and promotes cell death. Researchers highlighted the potential relevance for triple-negative breast cancer, an aggressive form that can spread quickly to other organs.

According to Izvestia, the nanoparticles are coated with beta-cyclodextrin, a substance obtained from starch that helps maintain their stability. Once inside cancer cells, they increase sensitivity to X-ray radiation. Preliminary tests also indicated that the nanoparticles have only a weak effect on blood cells, although one of the main challenges remains ensuring that they accumulate mainly in tumors and do not damage healthy tissue.

The development remains at the experimental stage. Scientists still need to test its safety and effectiveness first in animals and then in studies involving patients. If later stages are successful, the technology could support more targeted and less toxic radiation treatment. Earlier, Russian scientists also studied the possibility of detecting Alzheimer's disease through blood analysis; a study of 350 people showed that the concentration of a certain peptide in patients with the disease was almost twice as low as in the control group.

Source: podrobno.uz